Supportive treatments

Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…

Details

Related conditions

Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Ishiguro K et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.8999-17. [Epub ahead of print]. Metachronous solitary plasmacytoma. Khosa R et al. BMJ Case Rep. 2017 Oct 19;2017. pii: bcr-2017-221780. doi: 10.1136/bcr-2017-221780. Intratubular amyloid in light chain cast nephropathy is a risk factor for…

Details

General

A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Martino M et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021. [Epub ahead of print]. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the…

Details

Emerging treatments

Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma. Ghai A et al. J Nucl Med. 2017 Oct 12. pii: jnumed.117.196063. doi: 10.2967/jnumed.117.196063. [Epub ahead of print]. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Kumar S et al. Blood. 2017 Oct 10. pii: blood-2017-06-788786. doi: 10.1182/blood-2017-06-788786. [Epub ahead of print]. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus…

Details

Diagnostic techniques and prognostic indicators

Investigations of the Serum Free Light Chain Ratio According to the Updated 2014 IMWG Diagnostic Criteria for Multiple Myelomain Korean Patients with Newly Diagnosed Multiple Myeloma. Yang HS et al. Clin Lab. 2017 Oct 1;63(10):1765-1769. doi: 10.7754/Clin.Lab.2017.170341. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. Iaccino E et al. Mol Cancer. 2017 Oct 13;16(1):159. doi: 10.1186/s12943-017-0730-8. Chromothripsis in Treatment Resistance in Multiple…

Details

Current treatments

Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. Satin U et al. J Clin Apher. 2017 Oct 5. doi: 10.1002/jca.21591. [Epub ahead of print]. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Jeker B et al. Bone Marrow Transplant. 2017 Oct 23. doi: 10.1038/bmt.2017.234. [Epub ahead of print]. Phase II…

Details

Complications of myeloma and its treatments

A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Cracolici V et al. Head Neck Pathol. 2017 Oct 13. doi: 10.1007/s12105-017-0861-7. [Epub ahead of print]. Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy. Nakae Y et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.9096-17. [Epub ahead of print].…

Details

Biology and genetics

High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Sun Y et al. Cancer Lett. 2017 Oct 12. pii: S0304-3835(17)30629-8. doi: 10.1016/j.canlet.2017.10.005. [Epub ahead of print]. Characterization and use of the novel human multiple myelomacell line MC-b11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin a heavy chain. Walters DK et al. Exp Hematol. 2017 Oct 10. pii: S0301-472X(17)30814-7.…

Details

Phase III carfilzomib trial meets primary endpoint

Amgen has announced that its Phase III trial, ARROW, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared the effect of giving patients a higher dose of carfilzomib (Kyprolis®) once a week, compared to a smaller dose twice a week, together with dexamethasone. The…

Details